Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists

Area of Science:

• Medicinal Chemistry
• Computational Drug Design
• Neuroscience

Background:

• Identifying novel drug candidates is challenging due to saturated chemical space around established targets.
• The strychnine-insensitive Glycine binding site (Glycine(B) site) of the NMDA receptor is a key target for neurological drug discovery.
• Prior research has identified many potent lead structures, limiting innovation.

Purpose of the Study:

• To apply and validate state-of-the-art virtual screening techniques for identifying novel antagonists of the NMDA receptor's Glycine(B) site.
• To assess the novelty of identified compounds using scaffold analysis.
• To explore new chemical space for competitive drug candidates.

Main Methods:

• Virtual screening of 4.6 million chemical structures using Bayesian machine learning, automated molecular docking, pharmacophore search, pharmacophore quantitative structure-activity relationship (QSAR), and shape analysis.
• Scaffold analysis for novelty detection of virtual hits.
• In vitro testing of identified compounds.

Main Results:

• Multiple computational methods were applied to screen a large chemical library.
• Several novel, active compounds targeting the Glycine(B) site were identified through in vitro testing.
• Methods varied in their ability to detect novel compounds, with no single method proving superior for all aspects.

Conclusions:

• Focused compound library design and screening can still yield novel bioactive compounds, even for well-researched targets.
• The study highlights the potential for discovering compounds with unexplored scaffolds and novel variations of known chemotypes.
• A combination of computational methods is valuable, but novelty detection capabilities differ significantly.